Lexeo Therapeutics, Inc. Common Stock

LXEO: Is Lexeo Therapeutics, Inc. Common Stock Halal?

Lexeo Therapeutics, Inc. Common Stock

NASDAQHealthcareUS

$4.39

-1.79%

Market Cap: 344.7M

Compliance Status

Not Halal

Screened on Sep 1, 2026 · AAOIFI Standard 21

F

Non-Compliant

0Score

Is Lexeo Therapeutics, Inc. Common Stock (LXEO) halal? Not Halal. Based on AAOIFI screening, Lexeo Therapeutics, Inc. Common Stock passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Quote this verdict

HalalScreener rates Lexeo Therapeutics, Inc. Common Stock (LXEO) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Sep 1, 2026. Source: https://halalscreener.app/en/stock/LXEO

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

2.1% of 30.0% limit

What this means for you

Most scholars advise not holding LXEO

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

About Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Sep 1, 2026

Compliance History

  1. Not Halalnow

    since Aug 2026

  2. Under Review

    until the change above

  3. Not Halal

    until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: FY 2025Data source: FMP
Free · No credit card required

Track LXEO and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Lexeo Therapeutics, Inc. Common Stock (LXEO) halal to invest in?
Lexeo Therapeutics, Inc. Common Stock (LXEO) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.
Why did Lexeo Therapeutics, Inc. Common Stock get a F compliance rating?
Lexeo Therapeutics, Inc. Common Stock (LXEO) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 2.1% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Lexeo Therapeutics, Inc. Common Stock's Shariah verdict?
Lexeo Therapeutics, Inc. Common Stock's verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Lexeo Therapeutics, Inc. Common Stock re-screened for Shariah compliance?
Lexeo Therapeutics, Inc. Common Stock (LXEO) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Sep 1, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.